Eyenovia (NASDAQ:EYEN) Earns Hold Rating from Brookline Capital Management

Brookline Capital Management reiterated their hold rating on shares of Eyenovia (NASDAQ:EYEN) in a research note issued to investors on Friday morning,Benzinga reports.

EYEN has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Wednesday, November 13th. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a report on Friday.

Eyenovia Trading Up 8.9 %

Shares of EYEN stock opened at $0.11 on Friday. Eyenovia has a 1 year low of $0.09 and a 1 year high of $2.57. The firm has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27. The company has a market cap of $7.11 million, a price-to-earnings ratio of -0.15 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the prior year, the business posted ($0.18) earnings per share. As a group, equities analysts predict that Eyenovia will post -0.5 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael M. Rowe acquired 50,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This trade represents a 151.85 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 7.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eyenovia during the 2nd quarter valued at about $26,000. Ground Swell Capital LLC bought a new position in shares of Eyenovia during the 2nd quarter valued at about $27,000. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Eyenovia by 24.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the last quarter. Financial Management Network Inc. purchased a new stake in shares of Eyenovia during the 3rd quarter valued at about $39,000. Finally, SkyView Investment Advisors LLC purchased a new stake in shares of Eyenovia during the 2nd quarter valued at about $87,000. Institutional investors own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.